• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Sep. 2, 2014

View Archived Issues

In monkeys, Zmapp works against advanced Ebola, researchers report

Researchers reported Friday that in primates, the experimental antibody cocktail Zmapp could reverse Ebola disease in monkeys when it was administered up to five days after infection, at a point where the animals were severely ill. Read More

Zai zooms ahead with $30M series A from international investors

SHANGHAI – Zai Lab Inc., of Shanghai, has received $30 million in financing from a group of international venture capital investors, led by the well-respected Qiming Venture Partners LLC, headquartered in Hong Kong. The series A funding will support Zai's pursuit of its "virtual" business model, and the in-licensing and developing of innovative drugs for global markets as well as China. Read More

Anything but wingless, Oncomed slates phase II bounty in big year ahead

Oncomed Pharmaceuticals Inc.'s stoppage in June of phase Ib trials because of bone-related adverse events with a pair of candidates did little to dampen the enthusiasm of analysts for the firm, and last week's lift of the partial clinical hold on vantictumab (OMP-18R5) only made the picture brighter. Read More

Dezima's CETP inhibitor hits phase IIb endpoint

DUBLIN – Dezima Pharma BV is on track to move its highly potent cholesteryl ester transfer protein (CETP) inhibitor TA-8995 (DEZ-001) into a phase III program in the first quarter of next year, following a phase IIb dyslipidemia trial, which the drug passed with flying colors. Read More

Beyond child's play: Legochem's platform to expedite drug discovery

Legochem Biosciences Inc. (LCB) boasts an intuitive name, hearkening to the use of Lego-like scaffolds to enable the discovery of drug candidates. But the platform is more than a toy for scientists. Read More

Financings

Orexo AB, of Uppsala, Sweden, said it completed a private placement of approximately 2.5 million shares (STOCKHOLM:ORX), including all shares (approximately 1.1 million) held in its treasury plus approximately 1.4 million newly issued shares. Read More

In the clinic

Senesco Technologies Inc., of Bridgewater, N.J., said it closed enrollment in its ongoing open-label, multiple-dose, dose-escalation phase Ib/IIa trial of SNS01-T, a modulator of eukaryotic translation initiation factor 5A, or eIF5A, in patients with relapsed or refractory multiple myeloma, plasma cell leukemia or B-cell lymphoma. Read More

Stock movers

Read More

Holiday notice

BioWorld's offices were closed Monday, Sept. 1, in observance of the Labor Day holiday in the U.S. Read More

Other news to note

Intellipharmaceutics International Inc., of Toronto, said it improved the abuse-deterrence technology incorporated into its controlled-release oxycodone pill, Rexista, and that the approach is potentially applicable to a wide range of drugs. Read More

Bench Press: BioWorld looks at translational medicine

Researchers from the Broad Institute, Harvard University and the Kenema Government Hospital in Sierra Leone have reported sequencing results from 99 Ebola virus genomes isolated from 78 patients during the current large-scale outbreak in Western Africa, which has entrenched itself in larger cities as well as the remote areas where previous outbreaks were centered, and had claimed more than 1,350 victims as of last week. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 2, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 2, 2025.
  • Molecule illustration

    Unnatural Products joins Argenx in a $1.5B macrocyclic deal

    BioWorld
    Unnatural Products Inc. notched another collaboration by signing on with Argenx SE in a multitarget research collaboration. Unnatural Products, which is getting...
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • CMS logo and website

    CMS eyes competitive bidding for CGMs, insulin pumps

    BioWorld MedTech
    The U.S. Centers for Medicare & Medicaid Services posted the draft home health rule for calendar year 2026, which includes a proposal to subject continuous...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe